Innovent Biologics and Daiichi Sankyo have entered an exclusive agreement under which Daiichi Sankyo will handle development, manufacturing and supply of Vanflyta while Innovent holds sole commercialization rights and will lead market promotion in China.
The company claims Vanflyta was approved in China in June 2026 for use in combination with standard cytarabine and anthracycline induction, cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy for adult patients with newly diagnosed FLT3-ITD-positive acute myeloid leukemia, based on the QuANTUM-First trial.
The company claims Vanflyta (quizartinib) is an oral, highly potent type II FLT3 inhibitor that targets FLT3-ITD mutations.
Research cited in the release indicates more than 487,000 new global leukemia cases and over 305,000 deaths in 2022, with AML accounting for 23.1% of leukemia cases worldwide.
The release also notes nearly 82,000 leukemia diagnoses and more than 50,000 deaths in China in 2022, with AML representing about half of Chinese leukemia cases and FLT3-ITD mutations occurring in roughly 25% of AML cases.
